Merck

Merck Receives CHMP Positive Opinion For New Fertility Treatment, ELONVA(R)

Medical News Today (Free subscription) | 13 hours ago

Merck & Co., Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART)...

• Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R) - PR News Wire

Dell Tumbles 10%; Merck Gains

Law Blog - WSJ.com (Free subscription) | 22 hours ago

A bigger-than-expected drop in Dell's earnings and a pullback for global industrials, including Caterpillar, pushed stocks lower Friday, though continued strength for some defensive blue chips like Merck kept the Dow industrials in the black for the week.

Vitamin Beats Statin: Is Merck's Zetia in Trouble?

SeekingAlpha.com (Free subscription) | 22 hours ago

The Burrill Report submits: A small study is causing a big splash in the multi-billion dollar world of cholesterol treatments. The test, pitting a prescription form of the B vitamin niacin against the prescription drug ezetimibe, found that niacin significantly shrank artery walls when taken in combination with a statin. The commercial version of ezetimibe by contrast, sold by Merck ( MRK ) as Zetia,...

Ligand Earns $2 Million Merck Milestone

Contract Pharma Breaking News (Free subscription) | yesterday

Ligand Pharmaceuticals, Inc. has received $2 million in milestone payments from N. V. Organon, a subsidiary of Merck , through its research collaboration, which is due to expire at the end of December. “We have had a long and productive drug discovery relationship with Organon and Schering-Plough (which acquired Organon in November 2007) over the years for a range of research programs,”...

• Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc. - Business Wire

Merck fertility drug gets European recommendation

Seattle Times (Free subscription) | yesterday

Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.

Merck fertility drug gets European recommendation

Seattle Post-Intelligencer (Free subscription) | yesterday

WHITEHOUSE STATION, N.J. -- Drug developer Merck & Co. said Friday a European advisory committee recommended approval for the company's fertility drug Elonva.

Merck, Shopping in the UK?

In the Pipeline (Free subscription) | yesterday

So, according to this report , Merck is scouting out locations for a UK facility. No word if it's supposed to have a research component, but. . .as a correspondent points out, if only there were a large research campus that they could somehow get their hands on, convenient to both Cambridge and London, with all the facilities they might need. . .hmmm. . .

Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)

Red Orbit (Free subscription) | yesterday

WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc.

Merck KGaA cut to hold from buy at Citi

Market Watch (Free subscription) | yesterday

MADRID (MarketWatch) -- German pharmaceutical and chemical company Merck KGaA was downgraded to hold from buy on Friday at Citigroup, which said the risk-reward looks evenly balanced. The rejection of Erbitux by the Committee for Medicinal Products for Human Use on appeal in non-small lung cancer is a negative, said the analysts who are removing potential related sales from their forecast model. That's...

Ligand receives $2 million from Merck partnership

San Fransisco Chronicle (Free subscription) | 19/11/2009

Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co. as part of a research collaboration. The company said the partnership covers a range of research programs. It is due to expire at the end of December. Ligand... Merck & Co - Business - Pharmaceutical - Biotechnology and Pharmaceuticals - Schering-Plough

• Ligand receives $2 million from Merck partnership - Seattle Post-Intelligencer
• Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc. - Business Wire

Glaxo, Merck developing drugs for kala azar

Daily News Analysis (Free subscription) | 19/11/2009

Amid cancer, diabetes, strokes, flu, arthritis, etc, this life threatening disease, which affects millions of poor people in the world, finds negligible public attention or favour with drugmakers.

Ligand receives $2 million from Merck partnership

Seattle Times (Free subscription) | 19/11/2009

Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payment from Merck & Co. as part of a research collaboration.

Ligand receives $2 million from Merck partnership

Rocky Mount Telegram - Business (Free subscription) | 19/11/2009

SAN DIEGO — Ligand Pharmaceuticals Inc. said Thursday it received a $2 million milestone payme...

Ligand Nabs $2M From Merck

Xconomy (Free subscription) | 19/11/2009

San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today it has received $2 million in milestone payments as part of research collaboration with Merck that is due to expire next month. The partnership started with Organon, which was later acquired by Schering-Plough, which was then acquired by Merck.

• Ligand Earns $2 Million in Milestone Payments from Merck & Co., Inc. - Business Wire

Critical Alerts For Merck, Monsanto, Urban Outfitters, Petrohawk Energy, and Vistaprint Released By Seven Summits Research

PR News Wire (Free subscription) | 19/11/2009

CHICAGO, Nov. 19 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for MRK, MON, URBN, HK, and VPRT.